GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Qualis Innovations Inc (OTCPK:QLIS) » Definitions » ROC %

QLIS (Qualis Innovations) ROC % : -622.22% (As of Sep. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Qualis Innovations ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Qualis Innovations's annualized return on capital (ROC %) for the quarter that ended in Sep. 2024 was -622.22%.

As of today (2024-12-14), Qualis Innovations's WACC % is -5.79%. Qualis Innovations's ROC % is 1150.08% (calculated using TTM income statement data). Qualis Innovations generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Qualis Innovations ROC % Historical Data

The historical data trend for Qualis Innovations's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qualis Innovations ROC % Chart

Qualis Innovations Annual Data
Trend Jul06 Jul07 Jul08 Jul09 Jul10 Dec11 Dec21 Dec22 Dec23
ROC %
Get a 7-Day Free Trial Premium Member Only -490.78 8.53 -30.45 -263.33 -58.21

Qualis Innovations Quarterly Data
Apr11 Sep11 Dec11 Mar12 Jun12 Sep12 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -115.42 2,037.56 -24.71 -960.00 -622.22

Qualis Innovations ROC % Calculation

Qualis Innovations's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-0.202 * ( 1 - 0% )/( (0.185 + 0.509)/ 2 )
=-0.202/0.347
=-58.21 %

where

Qualis Innovations's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-0.084 * ( 1 - 0% )/( (0.016 + 0.011)/ 2 )
=-0.084/0.0135
=-622.22 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qualis Innovations  (OTCPK:QLIS) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Qualis Innovations's WACC % is -5.79%. Qualis Innovations's ROC % is 1150.08% (calculated using TTM income statement data). Qualis Innovations generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Qualis Innovations ROC % Related Terms

Thank you for viewing the detailed overview of Qualis Innovations's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Qualis Innovations Business Description

Traded in Other Exchanges
N/A
Address
6898 S. University Boulevard, Suite 100, Centennial, CO, USA, 80122
Qualis Innovations Inc. is the holding company of mPathix Health, Inc. The company is focused on the development, production, and distribution of multi-modal pain management and Central Nervous System related solutions. It develops pain management products using a modality-agnostic, virtual operating model. The company is developing a product designed to address the unmet needs of patients who seek alternatives to traditional pain medications and interventions or adjunctive therapies to their current treatment regimen.
Executives
Bin Wang director 112 RICO DR. NORTH, MORGANVILLE NJ 07751